Drug
Interleukin-2 clinical trials
Also written IL-2.
Counted the way a researcher would: Interleukin-2 with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Interleukin-2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Interleukin-2 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
212 studies that test it; most in 2012 (11)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1993 | 3 |
| 1994 | 2 |
| 1995 | 2 |
| 1996 | 1 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 3 |
| 2000 | 5 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 6 |
| 2004 | 8 |
| 2005 | 6 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 10 |
| 2012 | 11 |
| 2013 | 9 |
| 2014 | 9 |
| 2015 | 10 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 6 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 9 |
| 2024 | 9 |
| 2025 | 2 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 205
Peking University People's Hospital (19) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Dana-Farber Cancer Institute (9) · H. Lee Moffitt Cancer Center and Research Institute (9) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (8) · Masonic Cancer Center, University of Minnesota (6) · The First Affiliated Hospital with Nanjing Medical University (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (24) · Fludarabine (20) · Granulocyte-Macrophage Colony-Stimulating Factor (10) · Ipilimumab (6) · Sirolimus (5) · GP-100 antigen (5) · Aldesleukin (5) · Natural Killer Cell (4)
Related medicines
As reviewed, each with the page that says it.
- Aldesleukin is a recombinant medicine of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10
Studies that test Interleukin-2.
- Nov 2026Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian CancerPhase 1 · Dana-Farber Cancer Institute
- Dec 2026Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.Phase 2 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Dec 2026Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerPhase 1 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Jan 2027Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid TumorsEarly Phase 1 · Vall d'Hebron Institute of Oncology
- Feb 2027Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial CarcinomaEarly Phase 1 · Dana-Farber Cancer Institute
- Feb 2027Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationPhase 1 · Dana-Farber Cancer Institute
- Apr 2027A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.Phase 2 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Apr 2027Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic CancerPhase 2 · Sahlgrenska University Hospital
- Aug 2027HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)Phase 1 · Hangzhou Huasai Biomedicine Co., Ltd.
- Nov 2027Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsPhase 2 · The First Affiliated Hospital of Xiamen University
Studies
Open first, then newest update. How each study uses Interleukin-2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 216
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT07651319Written as IL-2 (Aldesleukin)
- HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07105176Written as IL-2 (interleukin 2)
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07830342Written as Interleukin 2 subcutaneous injection
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06047977Written as Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum DisorderNot yet recruitingPhase 2Peking University People's HospitalNCT07809724Written as IL-2 (interleukin 2)
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseRecruitingPhase 1David Bartlett, MDNCT07192900Written as Interleukin-2
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingPhase 1Dana-Farber Cancer InstituteNCT06138587Written as Interleukin-2
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06321484Written as Interleukin 2
- Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T CellsRecruitingNot applicableCambridge University Hospitals NHS Foundation TrustNCT07610538Written as Interleukin-2 (Aldesleukin)
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsRecruitingPhase 1Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)NCT07443020Written as Interleukin-2 (IL-2)
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingPhase 2Sheng-Li Xue, MDNCT05901974Written as azactidine
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Interleukin-2
- Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV ViremiaNot yet recruitingPhase 2Peking University People's HospitalNCT06971913Written as Interleukin-2 (IL-2)
- Efficacy of Interleukin-2 in Triple Negative Breast CancerNot yet recruitingPhase 1/2Nova Scotia Health AuthorityNCT05821686Written as Human Interleukin-2 (IL-2) (Proleukin)
- Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid TumorsRecruitingEarly Phase 1Vall d'Hebron Institute of OncologyNCT05141474Written as Interleukin-2
- A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.RecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT04166006Written as Interleukin-2
- Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid TumorsRecruitingPhase 1Guangzhou FineImmune Biotechnology Co., LTD.NCT03891706Written as Interleukin-2
- Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06584006Written as Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
- Phase II Clinical Trial of Interleukin-2 in ADRecruitingPhase 2The Methodist Hospital Research InstituteNCT06096090Written as Interleukin-2
- Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute ObstructionNot yet recruitingPhase 1/2The First Affiliated Hospital with Nanjing Medical UniversityNCT06394791Written as Tislelizumab + IL-2 Combined with Capox
See all 216 studies that test Interleukin-2 →
Given beside what is tested · 103 — Interleukin-2 is usual care or a partner of the new treatment
- Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingPhase 2Grit BiotechnologyNCT06241781Written as IL-2
- Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid TumorsRecruitingPhase 1/2Grit BiotechnologyNCT06144671Written as IL-2
- A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid TumorsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06598371Written as Interleukin-2
- NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid TumorsRecruitingPhase 1TCRCure Biopharma Ltd.NCT05881525Written as IL-2
- Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07770802Written as Interleukin 2 subcutaneous injection
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05681780Written as Interleukin-2 (IL2)
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Interleukin-2
- Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic MelanomaNot yet recruitingPhase 1Vastra Gotaland RegionNCT07183852Written as Interleukin-2
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingPhase 1Paolo Caimi, MDNCT07225439Written as Interleukin-2
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1Imugene LimitedNCT03666000Written as IL-2
- CIML NK Cells With Venetoclax for AMLRecruitingPhase 1Dana-Farber Cancer InstituteNCT06152809Written as Interleukin-2
- Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.Not yet recruitingPhase 1/2Gritbio Medicine, Inc.NCT07766317Written as IL-2 and PD-1
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaNot yet recruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT07700121Written as IL-2
- Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06961357Written as Interleukin-2
- A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCRecruitingPhase 1/2CuraCell TX ABNCT07255664Written as Interleukin-2
- Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARCRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07646639Written as Sintilimab + IL-2 Combined with CAPOX
- Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCTRecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07591649Written as IL-2
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as Interleukin-2
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingPhase 1/2Indapta Therapeutics, INC.NCT06119685Written as Interleukin-2
- Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid TumorsRecruitingPhase 1Guangzhou FineImmune Biotechnology Co., LTD.NCT06302062Written as IL-2
Showing 20 of 103.
As the comparator · 5 — what is tested is compared with Interleukin-2
- Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)RecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06630611Written as High dose IL-2
- Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.Active, not recruitingPhase 2Providence Health & ServicesNCT01416831Written as High-dose IL-2
- Natural Killer-cell Therapy for Acute Myeloid LeukemiaTerminatedPhase 1/2Radboud University Medical CenterNCT04347616Written as IL-2
- Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionStatus unknownNot applicablePeking Union Medical CollegeNCT04131231Written as recombinant human interleukin-2(rhIL-2)
- Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney CancerStatus unknownPhase 2University of AarhusNCT01274273Written as Interleukin-2
Codes
What other systems call Interleukin-2 · ClinicalTrials.gg INT007673
- MeSH (NLM) D007376Interleukin-2One source ClinicalTrials.gov
- UNII (FDA) FNO32LO217HUMAN INTERLEUKIN-2One source FDA
- NCI Thesaurus C587Recombinant Interleukin-2One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007376 | Interleukin-2 | One source ClinicalTrials.gov |
| UNII (FDA) | FNO32LO217 | HUMAN INTERLEUKIN-2 | One source FDA |
| NCI Thesaurus | C587 | Recombinant Interleukin-2 | One source FDA |
Also registered as teceleukin (UNII H5ZRB188EI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.